PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
October 17, 2022 at 04:05 pm EDT
Share
EQS Voting Rights Announcement: QIAGEN N.V.
QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
17.10.2022 / 22:04 CET/CEST
Dissemination of a Voting Rights Announcement transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The AFM (the Netherlands Authority For the Financial Markets has informed us on October 14, 2022 that a notification related to our institution has been released by the AFM.
The following notification has been disclosed in the relevant register on the AFM website:
Date of transaction: 10 Oct 2022
Person obliged to notify: Goldman Sachs Group Inc., The
Issuing institution: Qiagen N.V.
Registration Chamber of Commerce: 12036979
Place of residence: VENLO
Distribution in numbers
Type of share
Number of shares
Number of voting rights
Capital interest
Voting rights
Manner of disposal
Settlement
Ordinary share
6.924,00
6.924,00
Real
Real
Indirectly - The Goldman Sachs Trust Company of Delaware
Physical Delivery
Ordinary share
15.579,00
15.578,84
Real
Real
Indirectly - NN Investment Partners Holdings B.V.
Physical Delivery
put option
90.000,00
90.000,00
Potential
Potential
Indirectly - Goldman Sachs International
Physical Delivery
Ordinary share
387.380,00
387.380,00
Potential
Potential
Indirectly - Goldman Sachs & Co. LLC
Physical Delivery
Convertible bond
530.331,00
530.331,00
Potential
Potential
Indirectly - NN Investment Partners Holdings B.V.
Physical Delivery
Ordinary share
210.500,00
210.500,00
Real
Real
Indirectly - Goldman Sachs Bank Europe SE
Physical Delivery
Warrant
61.199,00
61.199,00
Potential
Potential
Indirectly - Goldman Sachs Bank Europe SE
In cash
Swap
300.153,00
300.153,00
Potential
Potential
Indirectly - Goldman Sachs International
In cash
Option
3.863.782,00
3.863.782,00
Potential
Potential
Indirectly - Goldman Sachs & Co. LLC
Physical Delivery
Ordinary share
11,00
11,00
Potential
Potential
Indirectly - Goldman Sachs Bank Europe SE
Physical Delivery
Swap
46.540,00
46.540,00
Potential
Potential
Indirectly - Goldman Sachs & Co. LLC
In cash
Call-Option
375.000,00
375.000,00
Potential
Potential
Indirectly - Goldman Sachs International
Physical Delivery
Ordinary share
5.503,00
5.503,00
Real
Real
Indirectly - United Capital Financial Advisers, LLC
Physical Delivery
Ordinary share
42,00
42,00
Real
Real
Indirectly - Folio Investments, Inc.
Physical Delivery
Ordinary share
581.515,00
581.515,00
Potential
Potential
Indirectly - Goldman Sachs International
Physical Delivery
Convertible bond
419.014,00
419.014,00
Potential
Potential
Indirectly - Goldman Sachs International
Physical Delivery
Distribution in percentages
Type
Total holding
Directly real
Directly potential
Indirectly real
Indirectly potential
Capital interest
2,99%
0,00%
0,00%
0,10%
2,88%
Voting rights
2,99%
0,00%
0,00%
0,10%
2,88%
QIAGEN N.V. is not responsible for the accuracy and correctness of the notification above. The content has
17.10.2022 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.